Phenotypic and functional deficiencies of leukaemic dendritic cells from patients with chronic myeloid leukaemia
- 20 December 2002
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 120 (1) , 63-73
- https://doi.org/10.1046/j.1365-2141.2003.03979.x
Abstract
Summary. Chronic myeloid leukaemia (CML) dendritic cells (DC) are possible candidates for inducing antileukaemic immunity. This study aimed to investigate the frequency, phenotype and function of blood‐derived leukaemic DC in comparison with DC from healthy donors using flow cytometric assays and mixed leucocyte reaction (MLR). Immature leukaemic DC displayed a reduced endocytotic capacity as compared with healthy controls. Moreover, in vitro maturation of leukaemic DC was found to be deficient. Expression of CD80, CD83, CD86, and major histocompatibility complex class I and class II antigens were reduced on lipopolysaccharide (LPS)‐matured leukaemic DC but were enhanced by a mixture of interleukin 1β (IL‐1β), IL‐6, tumour necrosis factor‐α (TNF‐α) and prostaglandin E2 (PGE2). Upon stimulation with bacterial LPS, intracellular TNF‐α and IL‐8 production was diminished in maturing DC from CML patients. This distinct cytokine deficiency was overcome when leukaemic DC were stimulated with cytokines/PGE2. MLR showed fully functional leukaemic DC after TNF‐α‐induced maturation, but a reduced proliferative alloresponse of leukaemic peripheral blood mononuclear cells. Further, intracellular production of cytokines in CML‐derived T cells was markedly reduced. These data indicated that, in CML, the maturation response of leukaemic monocyte‐derived DC to a natural stimulus like LPS is abnormal and may be caused by an aberrant TNF‐α response in these cells. Thus, TNF‐α alone or in combination with pro‐inflammatory and T‐cell stimulatory cytokines should be considered as an adjuvant for DC‐based immunotherapy in CML.Keywords
This publication has 46 references indexed in Scilit:
- Leukemia blast-induced T-cell anergy demonstrated by leukemia-derived dendritic cells in acute myelogenous leukemiaExperimental Hematology, 2001
- Clonal heterogeneity of dendritic cells derived from patients with chronic myeloid leukemia and enhancement of their T-cells stimulatory activity by IFN-αExperimental Hematology, 1999
- Phenotypic and Functional Properties of Dendritic Cells Isolated from Human Peripheral Blood in Comparison with Mononuclear Cells and T CellsScandinavian Journal of Immunology, 1999
- Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.Journal of Clinical Investigation, 1998
- Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cellsHuman Immunology, 1997
- Origin, maturation and antigen presenting function of dendritic cellsCurrent Opinion in Immunology, 1997
- Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products.The Journal of Experimental Medicine, 1995
- Proliferating dendritic cell progenitors in human blood.The Journal of Experimental Medicine, 1994
- Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.The Journal of Experimental Medicine, 1994
- Assessment of Cytokines by Immunofluorescence and the Paraformaldehyde‐Saponin ProcedureImmunological Reviews, 1991